Lenalidomide in diffuse large B-cell lymphoma

Advances in Hematology

Volumn 2012, Issue , 2012, Pages

  Thieblemont, Catherine ^a   Delfau Larue, Marie Hélène ^b   Coiffier, Bertrand ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LENALIDOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VINCRISTINE; VINDESINE;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIPROLIFERATIVE ACTIVITY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DEEP VEIN THROMBOSIS; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; IMMUNOMODULATION; LARGE CELL LYMPHOMA; LYMPHOMA; MEDICAL LITERATURE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REGULATORY T LYMPHOCYTE; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 84871425422     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2012/861060     Document Type: Review

References (62)

1. The Non-Hodgkin's Lymphoma Classification Project, A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997 89 11 3909 3918 2-s2.0-1842413105
2. Percy C., O'Conor G., Ries L. G., Jaffe E. S., Non-Hodgkin's lymphomas. Application of the international classification of diseases for oncology (ICD-O) to the working formulation. Cancer 1984 54 7 1435 1438 2-s2.0-0021162464 (Pubitemid 14003548)
3. Swerdlow S. H., Campo E., Harris N. L., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 Lyon, France IARC Press
4. Alizadeh A. A., Elsen M. B., Davis R. E., Ma C. L., Lossos I. S., Rosenwald A., Boldrick J. C., Sabet H., Tran T., Yu X., Powell J. I., Yang L., Marü G. E., Moore T., Hudson J., Lu L., Lewis D. B., Tibshirani R., Sherlock G., Chan W. C., Greiner T. C., Weisenburger D. D., Armitage J. O., Warnke R., Levy R., Wilson W., Grever M. R., Byrd J. C., Botstein D., Brown P. O., Staudt L. M., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403 6769 503 511 2-s2.0-0034598746 10.1038/35000501 (Pubitemid 30082188)
5. Lenz G., Wright G., Dave S. S., Xiao W., Powell J., Zhao H., Xu W., Tan B., Goldschmidt N., Iqbal J., Vose J., Bast M., Fu K., Weisenburger D. D., Greiner T. C., Armitage J. O., Kyle A., May L., Gascoyne R. D., Connors J. M., Troen G., Holte H., Kvaloy S., Dierickx D., Verhoef G., Delabie J., Smeland E. B., Jares P., Martinez A., Lopez-Guillermo A., Montserrat E., Campo E., Braziel R. M., Miller T. P., Rimsza L. M., Cook J. R., Pohlman B., Sweetenham J., Tubbs R. R., Fisher R. I., Hartmann E., Rosenwald A., Ott G., Muller-Hermelink H.-K., Wrench D., Lister T. A., Jaffe E. S., Wilson W. H., Chan W. C., Staudt L. M., Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine 2008 359 22 2313 2323 2-s2.0-70350447494 10.1056/NEJMoa0802885
6. Coiffier B., Lepage E., Brière J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C., Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 2002 346 4 235 242 2-s2.0-0037165261 10.1056/NEJMoa011795 (Pubitemid 34438862)
7. Feugier P., van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., Coiffier B., Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d'etude des lymphomes de l'adulte. Journal of Clinical Oncology 2005 23 18 4117 4126 2-s2.0-23044503407 10.1200/JCO.2005.09.131 (Pubitemid 46211317)
8. Coiffier B., Thieblemont C., van den Neste E., Lepeu G., Plantier I., Castaigne S., Lefort S., Marit G., Macro M., Sebban C., Belhadj K., Bordessoule D., Fermé C., Tilly H., Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010 116 12 2040 2045 2-s2.0-77957200763 10.1182/blood-2010-03- 276246
9. Klapper W., Stoecklein H., Zeynalova S., Ott G., Kosari F., Rosenwald A., Loeffler M., Trümper L., Pfreundschuh M., Siebert R., Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008 22 12 2226 2229 2-s2.0-57849149430 10.1038/leu.2008.230
10. Tilly H., Lepage E., Coiffier B., Blanc M., Herbrecht R., Bosly A., Attal M., Fillet G., Guettier C., Molina T. J., Gisselbrecht C., Reyes F., Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003 102 13 4284 4289 2-s2.0-10744224285 10.1182/blood-2003-02-0542 (Pubitemid 37494085)
11. Wilson W. H., Dunleavy K., Pittaluga S., Hegde U., Grant N., Steinberg S. M., Raffeld M., Gutierrez M., Chabner B. A., Staudt L., Jaffe E. S., Janik J. E., Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. Journal of Clinical Oncology 2008 26 16 2717 2724 2-s2.0-45749152667 10.1200/JCO.2007.13.1391
12. Récher C., Coiffier B., Haioun C., Molina T. J., Fermé C., Casasnovas O., Thiéblemont C., Bosly A., Laurent G., Morschhauser F., Ghesquires H., Jardin F., Bologna S., Fruchart C., Corront B., Gabarre J., Bonnet C., Janvier M., Canioni D., Jais J.-P., Salles G., Tilly H., Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. The Lancet 2011 378 9806 1858 1867 2-s2.0-20144369743 10.1016/S0140-6736(11)61040-4
13. Reyes F., Lepage E., Ganem G., Molina T. J., Brice P., Coiffier B., Morel P., Ferme C., Bosly A., Lederlin P., Laurent G., Tilly H., ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. New England Journal of Medicine 2005 352 12 1197 1205 2-s2.0-20144369743 10.1056/NEJMoa042040 (Pubitemid 40397261)
14. Bartlett J. B., Dredge K., Dalgleish A. G., The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews Cancer 2004 4 4 314 322 2-s2.0-1942534043 (Pubitemid 38525287)
15. Rosenwald A., Wright G., Chan W. C., Connors J. M., Campo E., Fisher R. I., Gascoyne R. D., Konrad Muller-Hermelink H., Smeland E. B., Giltnane J. M., Hurt E. M., Zhao H., Averett L., Yang L., Wilson W. H., Jaffe E. S., Simon R., Klausner R. D., Powell J., Duffey P. L., Longo D. L., Greiner T. C., Weisenburger D. D., Sanger W. G., Dave B. J., Lynch J. C., Vose J., Armitage J. O., Montserrat E., López-Guillermo A., Grogan T. M., Miller T. P., Leblanc M., Ott G., Kvaloy S., Delabie J., Holte H., Krajci P., Stokke T., Staudt L. M., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine 2002 346 25 1937 1947 2-s2.0-0242693932 10.1056/NEJMoa012914 (Pubitemid 34651353)
16. Gratzinger D., Zhao S., Tibshirani R. J., Hsi E. D., Hans C. P., Pohlman B., Bast M., Avigdor A., Schiby G., Nagler A., Byrne G. E., Lossos I. S., Natkunam Y., Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Laboratory Investigation 2008 88 1 38 47 2-s2.0-37549055122 10.1038/labinvest.3700697
17. Cardesa-Salzmann T. M., Colomo L., Gutierrez G., Chan W. C., Weisenburger D., Climent F., González-Barca E., Mercadal S., Arenillas L., Serrano S., Tubbs R., Delabie J., Gascoyne R. D., Connors J. M., Mate J. L., Rimsza L., Braziel R., Rosenwald A., Lenz G., Wright G., Jaffe E. S., Staudt L., Jares P., López-Guillermo A., Campo E., High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 2011 96 7 996 1001 2-s2.0-79959944338 10.3324/haematol.2010.037408
18. Koster A., Raemaekers J. M. M., Angiogenesis in malignant lymphoma. Current Opinion in Oncology 2005 17 6 611 616 2-s2.0-27644431763 10.1097/01.cco.0000181404.83084.b5 (Pubitemid 41566417)
19. Ruan J., Hajjar K., Rafii S., Leonard J. P., Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Annals of Oncology 2009 20 3 413 424 2-s2.0-61649123322 10.1093/annonc/mdn666
20. Reddy N., Hernandez-Ilizaliturri F. J., Deeb G., Roth M., Vaughn M., Knight J., Wallace P., Czuczman M. S., Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British Journal of Haematology 2008 140 1 36 45 2-s2.0-36849024949 10.1111/j.1365-2141. 2007.06841.x (Pubitemid 350233246)
21. Lu L., Payvandi F., Wu L., Zhang L. H., Hariri R. J., Man H. W., Chen R. S., Muller G. W., Hughes C. C. W., Stirling D. I., Schafer P. H., Bartlett J. B., The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvascular Research 2009 77 2 78 86 2-s2.0-60449115552 10.1016/j.mvr.2008.08.003
22. Monti S., Savage K. J., Kutok J. L., Feuerhake F., Kurtin P., Mihm M., Wu B., Pasqualucci L., Neuberg D., Aguiar R. C. T., Cin P. D., Ladd C., Pinkus G. S., Salles G., Harris N. L., Dalla-Favera R., Habermann T. M., Aster J. C., Golub T. R., Shipp M. A., Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005 105 5 1851 1861 2-s2.0-20144382754 10.1182/blood-2004-07- 2947 (Pubitemid 40731764)
23. Habermann T. M., Wang S. S., Maurer M. J., Morton L. M., Lynch C. F., Ansell S. M., Hartge P., Severson R. K., Rothman N., Davis S., Geyer S. M., Cozen W., Chanock S. J., Cerhan J. R., Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008 112 7 2694 2702 2-s2.0-53449095327 10.1182/blood-2007-09-111658
24. Lech-Maranda E., Bienvenu J., Broussais-Guillaumot F., Warzocha K., Michallet A. S., Robak T., Coiffier B., Salles G., Plasma TNF- α and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-cell lymphoma in different risk groups defined by the international prognostic index. Archivum Immunologiae et Therapiae Experimentalis 2010 58 2 131 141 2-s2.0-77952781844 10.1007/s00005-010-0066-1
25. Corral L. G., Haslett P. A. J., Muller G. W., Chen R., Wong L. M., Ocampo C. J., Patterson R. T., Stirling D. I., Kaplan G., Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF- α Journal of Immunology 1999 163 1 380 386 2-s2.0-0033168605 (Pubitemid 29295864)
26. + T cells. Clinical and Experimental Immunology 2002 130 1 75 84 2-s2.0-0036381106 10.1046/j.1365-2249.2002.01954.x
27. Caligiuri M. A., Human natural killer cells. Blood 2008 112 3 461 469 2-s2.0-50949124847 10.1182/blood-2007-09-077438
28. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S., Functions of natural killer cells. Nature Immunology 2008 9 5 503 510 2-s2.0-42449151214 10.1038/ni1582 (Pubitemid 351560519)
29. Street S. E. A., Hayakawa Y., Zhan Y., Lew A. M., MacGregor D., Jamieson A. M., Diefenbach A., Yagita H., Godfrey D. I., Smyth M. J., Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and γ δ T cells. Journal of Experimental Medicine 2004 199 6 879 884 2-s2.0-12144290645 10.1084/jem.20031981 (Pubitemid 38375207)
30. Challa-Malladi M., Lieu Y. K., Califano O., Holmes A. B., Bhagat G., Murty V., Dominguez-Sola D., Pasqualucci L., Dalla-Favera R., Combined genetic inactivation of β 2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011 20 6 728 740 2-s2.0-83555173561 10.1016/j.ccr.2011.11.006
31. Barber D. F., Faure M., Long E. O., LFA-1 contributes an early signal for NK cell cytotoxicity. Journal of Immunology 2004 173 6 3653 3659 2-s2.0-4644324573 (Pubitemid 39280725)
32. Plonquet A., Haioun C., Jais J. P., Debard A. L., Salles G., Bene M. C., Feugier P., Rabian C., Casasnovas O., Labalette M., Kuhlein E., Farcet J. P., Emile J. F., Gisselbrecht C., Delfau-Larue M. H., Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Annals of Oncology 2007 18 7 1209 1215 2-s2.0-34547840267 10.1093/annonc/mdm110 (Pubitemid 47244368)
33. Zitvogel L., Kepp O., Kroemer G., Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews Clinical Oncology 2011 8 3 151 160 2-s2.0-79952390627 10.1038/nrclinonc.2010.223
34. Davis R. E., Brown K. D., Siebenlist U., Staudt L. M., Constitutive nuclear factor B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. Journal of Experimental Medicine 2001 194 12 1861 1874 2-s2.0-0035905313 10.1084/jem.194.12.1861 (Pubitemid 34028664)
35. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., Kumar S., Chauhan D., Treon S. P., Richardson P., Anderson K. C., Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology 2005 128 2 192 203 2-s2.0-19944430437 10.1111/j.1365-2141.2004.05286.x
36. Hsu A. K., Quach H., Tai T., Prince H. M., Harrison S. J., Trapani J. A., Smyth M. J., Neeson P., Ritchie D. S., The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011 117 5 1605 1613 2-s2.0-79551615800 10.1182/blood-2010-04-278432
37. Habermann T. M., Weller E. A., Morrison V. A., Gascoyne R. D., Cassileth P. A., Cohn J. B., Dakhil S. R., Woda B., Fisher R. I., Peterson B. A., Horning S. J., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology 2006 24 19 3121 3127 2-s2.0-33745982067 10.1200/JCO.2005.05.1003 (Pubitemid 46638950)
38. Pfreundschuh M., Trümper L., Österborg A., Pettengell R., Trneny M., Imrie K., Ma D., Gill D., Walewski J., Zinzani P. L., Stahel R., Kvaloy S., Shpilberg O., Jaeger U., Hansen M., Lehtinen T., López- Guillermo A., Corrado C., Scheliga A., Milpied N., Mendila M., Rashford M., Kuhnt E., Loeffler M., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology 2006 7 5 379 391 2-s2.0-33646004738 10.1016/S1470-2045(06)70664-7
39. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G., Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Research 2004 64 13 4664 4669 2-s2.0-3042743884 10.1158/0008-5472.CAN-03-2862 (Pubitemid 38856941)
40. Ahlgrimm M., Pfreundschuh M., Kreuz M., Regitz E., Preuss K.-D., Bittenbring J., The impact of Fc- γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 2011 118 17 4657 4662 2-s2.0-80055101171 10.1182/blood-2011-04- 346411
41. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc γ rIIIa gene. Blood 2002 99 3 754 758 2-s2.0-0036464719 10.1182/blood.V99.3.754 (Pubitemid 34525533)
42. + tumor cells. Clinical Cancer Research 2008 14 14 4650 4657 2-s2.0-51649123319 10.1158/1078-0432.CCR-07-4405
43. Yamaguchi T., Sakaguchi S., Regulatory T cells in immune surveillance and treatment of cancer. Seminars in Cancer Biology 2006 16 2 115 123 2-s2.0-31644432589 10.1016/j.semcancer.2005.11.005 (Pubitemid 43172060)
44. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006 107 9 3639 3646 2-s2.0-33646422454 10.1182/blood-2005-08- 3376
45. + regulatory T cells predicts outcome in diffuse large B-cell lymphoma. British Journal of Haematology 2007 137 4 364 373 2-s2.0-34247549368 10.1111/j.1365-2141.2007.06593.x (Pubitemid 46650261)
46. + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008 93 2 193 200 2-s2.0-40849126992 10.3324/haematol.11702 (Pubitemid 351397707)
47. Hans C. P., Weisenburger D. D., Greiner T. C., Gascoyne R. D., Delabie J., Ott G., Müller H. K., Campo E., Braziel R. M., Jaffe E. S., Pan Z., Farinha P., Smith L. M., Falini B., Banham A. H., Rosenwald A., Staudt L. M., Connors J. M., Armitage J. O., Chan W. C., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004 103 1 275 282 2-s2.0-9144237554 10.1182/blood-2003-05-1545 (Pubitemid 38029949)
48. Ménétrier-Caux C., Gobert M., Caux C., Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Research 2009 69 20 7895 7898 2-s2.0-70350238332 10.1158/0008-5472.CAN- 09-1642
49. Galustian C., Meyer B., Labarthe M. C., Dredge K., Klaschka D., Henry J., Todryk S., Chen R., Muller G., Stirling D., Schafer P., Bartlett J. B., Dalgleish A. G., The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunology, Immunotherapy 2009 58 7 1033 1045 2-s2.0-67349107194 10.1007/s00262-008-0620-4
50. Shaffer A. L. III, Young R. M., Staudt L. M., Pathogenesis of human B cell lymphomas. Annual Review of Immunology 2012 30 565 610 10.1146/annurev- immunol-020711-075027
51. Hernandez-Ilizaliturri F. J., Reddy N., Holkova B., Ottman E., Czuczman M. S., Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clinical Cancer Research 2005 11 16 5984 5992 2-s2.0-23844435619 10.1158/1078-0432.CCR- 05-0577 (Pubitemid 41170330)
52. Wiernik P. H., Lossos I. S., Tuscano J. M., Justice G., Vose J. M., Cole C. E., Lam W., McBride K., Wride K., Pietronigro D., Takeshita K., Ervin-Haynes A., Zeldis J. B., Habermann T. M., Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 2008 26 30 4952 4957 2-s2.0-54449095901 10.1200/JCO.2007.15.3429
53. Witzig T. E., Vose J. M., Zinzani P. L., Reeder C. B., Buckstein R., Polikoff J. A., Bouabdallah R., Haioun C., Tilly H., Guo P., Pietronigro D., Ervin-Haynes A. L., Czuczman M. S., An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Annals of Oncology 2011 22 7 1622 1627 2-s2.0-79959722615 10.1093/annonc/mdq626
54. Zinzani P. L., Pellegrini C., Gandolfi L., Stefoni V., Quirini F., Derenzini E., Broccoli A., Argnani L., Pileri S., Baccarani M., Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clinical Lymphoma, Myeloma and Leukemia 2011 11 6 462 466 2-s2.0-84857654592 10.1016/j.clml.2011.02.001
55. Czuczman M. S., Vose J. M., Witzig T. E., Zinzani P. L., Buckstein R., Polikoff J., Li J., Pietronigro D., Ervin-Haynes A., Reeder C. B., The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. British Journal of Haematology 2011 154 4 477 481 2-s2.0-79960834399 10.1111/j.1365-2141.2011.08781.x
56. Nowakowski G. S., LaPlant B., Habermann T. M., Rivera C. E., Macon W. R., Inwards D. J., Micallef I. N., Johnston P. B., Porrata L. F., Ansell S. M., Klebig R. R., Reeder C. B., Witzig T. E., Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011 25 1877 1881 2-s2.0-79959633561 10.1038/leu.2011.165
57. Vitolo U., Chiappella A., Carella A., Prospective, multicenter phase I-II pilot trial to evaluate efficacy and safety of lenalidomide plus rituximab-CHOP21 (LR-CHOP21) for elderly patients with untreated diffuse large B-Cell lymphoma (DLBCL): interim analysis of the intergruppo italiano linfomi (IIL) REAL07 study. Blood 2010 116 2871. ASH Annual Meeting Abstracts
58. Tilly H., Morschhauser F., Salles G.,: Phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-Cell lymphomas. Blood 2011 118 1632. ASH Annual Meeting Abstracts
59. Rigacci L., Zaja F., Fabbri A., Lenalidomide administration in heavily pretreated patients with non hodgkin lymphoma-first report of the REVEAL study (REVlimid effectiveness of administration in patients with lymphoma). Blood 2011 118. ASH Annual Meeting Abstracts, Abstract 4979
60. Cheson B. D., Pfistner B., Juweid M. E., Gascoyne R. D., Specht L., Horning S. J., Coiffier B., Fisher R. I., Hagenbeek A., Zucca E., Rosen S. T., Stroobants S., Lister T. A., Hoppe R. T., Dreyling M., Tobinai K., Vose J. M., Connors J. M., Federico M., Diehl V., Revised response criteria for malignant lymphoma. Journal of Clinical Oncology 2007 25 5 579 586 2-s2.0-33947496614 10.1200/JCO.2006.09.2403 (Pubitemid 350002966)
61. Hernandez-Ilizaliturri F. J., Deeb G., Zinzani P. L., Pileri S. A., Malik F., Macon W. R., Goy A., Witzig T. E., Czuczman M. S., Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center b-cell-like than in germinal center b-cell-like phenotype. Cancer 2011 117 22 5058 5066 2-s2.0-79953841441 10.1002/cncr.26135
62. Reeder C. B., Ansell S. M., Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 2011 117 5 1453 1462 2-s2.0-79551623391 10.1182/blood-2010-06-255067